A drug-likeness toolbox facilitates ADMET study in drug discovery

Drug Discov Today. 2020 Jan;25(1):248-258. doi: 10.1016/j.drudis.2019.10.014. Epub 2019 Nov 6.

Abstract

Undesirable pharmacokinetic (PK) properties or unacceptable toxicity are the main causes of the failure of drug candidates at the clinical trial stage. Since the concept of drug-likeness was first proposed, it has become an important consideration in the selection of compounds with desirable bioavailability during the early phases of drug discovery. Over the past decade, online resources have effectively facilitated drug-likeness studies in an economical and time-efficient manner. Here, we provide a comprehensive summary and comparison of current accessible online resources, in terms of their key features, application fields, and performance for in silico drug-likeness studies. We hope that the assembled toolbox will provide useful guidance to facilitate future in silico drug-likeness research.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Biological Products
  • Databases, Factual
  • Drug Discovery*
  • Humans
  • Pharmaceutical Preparations / metabolism
  • Pharmacokinetics

Substances

  • Biological Products
  • Pharmaceutical Preparations